A detailed history of Price T Rowe Associates Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 7,352,277 shares of LYEL stock, worth $4.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,352,277
Previous 7,872,369 6.61%
Holding current value
$4.56 Million
Previous $11.4 Million 11.12%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.13 - $1.88 $587,703 - $977,772
-520,092 Reduced 6.61%
7,352,277 $10.1 Million
Q2 2024

Aug 14, 2024

BUY
$1.3 - $3.01 $1.48 Million - $3.43 Million
1,140,892 Added 16.95%
7,872,369 $11.4 Million
Q1 2024

May 15, 2024

BUY
$1.71 - $3.07 $158,335 - $284,263
92,594 Added 1.39%
6,731,477 $15 Million
Q4 2023

Feb 14, 2024

SELL
$1.39 - $2.35 $65,766 - $111,187
-47,314 Reduced 0.71%
6,638,883 $12.9 Million
Q3 2023

Nov 14, 2023

SELL
$1.45 - $3.35 $2.14 Million - $4.94 Million
-1,474,897 Reduced 18.07%
6,686,197 $9.83 Million
Q2 2023

Aug 14, 2023

BUY
$1.89 - $3.86 $7.93 Million - $16.2 Million
4,193,756 Added 105.71%
8,161,094 $26 Million
Q1 2023

May 15, 2023

BUY
$1.97 - $3.58 $574,554 - $1.04 Million
291,652 Added 7.93%
3,967,338 $9.36 Million
Q4 2022

Feb 14, 2023

SELL
$2.78 - $8.09 $4.53 Million - $13.2 Million
-1,630,921 Reduced 30.73%
3,675,686 $12.8 Million
Q3 2022

Nov 14, 2022

SELL
$5.54 - $8.27 $115,725 - $172,752
-20,889 Reduced 0.39%
5,306,607 $38.9 Million
Q2 2022

Aug 15, 2022

SELL
$3.68 - $6.8 $612,447 - $1.13 Million
-166,426 Reduced 3.03%
5,327,496 $34.7 Million
Q1 2022

May 16, 2022

BUY
$5.05 - $7.7 $1.78 Million - $2.72 Million
352,631 Added 6.86%
5,493,922 $27.7 Million
Q4 2021

Feb 14, 2022

BUY
$7.13 - $15.19 $10.6 Million - $22.5 Million
1,482,021 Added 40.5%
5,141,291 $39.8 Million
Q3 2021

Nov 15, 2021

BUY
$11.0 - $17.95 $12.8 Million - $20.8 Million
1,159,270 Added 46.37%
3,659,270 $54.2 Million
Q2 2021

Aug 16, 2021

BUY
$15.99 - $16.89 $40 Million - $42.2 Million
2,500,000 New
2,500,000 $40.6 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $154M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.